Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

Learn more about whether Elanco Animal Health Incorporated or Harmony Biosciences Holdings, Inc. is a better investment based ...

Rigel Pharmaceuticals, Inc.  today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience ...

Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational ...

Kate Therapeutics' pipeline is still in the preclinical stage of development but includes candidates for DMD, facioscapulohumeral dystrophy (FSHD), and myotonic dystrophy type 1 (DM1), as well as ...

The most common cause of ptosis with heightened lid crease is the levator dehiscence–disinsertion syndrome (see below ... Myotonia is seen in myotonic dystrophy as well as the non-dystrophic myotonias ...

Results Home NIV was initiated in 1746 patients to treat chronic ventilatory failure caused by (1) obesity hypoventilation syndrome±obstructive sleep ... Duchenne muscular dystrophy, myotonic ...

Myotonic dystrophy type 1 (DM1) is the most common adult-onset form of muscular dystrophy and a condition that severely ...

Myotonic dystrophy type 1 (DM1), a genetic disorder, shares overlapping features with chronic kidney disease, including ...

About the rSM Program to Treat Myotonic Dystrophy Type 1 (DM1) Myotonic dystrophy type 1 (DM1) is a form of muscular dystrophy and a genetic neuromuscular disease affecting at least 1 in 8,000 ...

How would you summarize your study for a lay audience? Myotonic dystrophy type 1 (DM1), a genetic disorder, shares overlapping features with chronic kidney disease, including progressive muscle ...